Announcement PDF 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Phase 1 SPONTAN® Nasal Spray Study Accepted for Podium Presentation at World Meeting on Sexual Medicine 2026 08 January 2026 Highlights  Independent Phase 1 data supporting rapid absorption of SPONTAN® validated by podium acceptance at a leading global scientific congress  SPONTAN® nasal spray achieved notably shorter time to peak concentration (Tmax) compared to oral vardenafil tablets  Higher dose-normalised bioavailability observed with SPONTAN® despite a lower administered dose, with a well-tolerated safety profile LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that an abstract relating to its Phase 1 clinical study of SPONTAN® has been accepted for podium (oral) presentation at the World Meeting on Sexual Medicine (WMSM) 2026, organised by the International Society of Sexual Medicine (ISSM). The abstract, entitled “Evaluation of Pharmacokinetics Profile and Safety Outcomes Comparing Nasal SPONTAN versus Oral Vardenafil Formulations”, will be presented by Professor Eric Chung and reports results from a Phase 1, open-label, randomised, single-dose crossover study conducted in healthy adult males. The study compared SPONTAN nasal spray (vardenafil 5 mg) with oral vardenafil tablets (10 mg). It assessed key pharmacokinetic parameters, including time to maximum plasma concentration (Tmax), maximum concentration (Cmax), overall drug exposure (AUC), half-life, and safety outcomes. The study demonstrated that SPONTAN nasal spray achieved faster drug absorption, with a notably shorter median Tmax compared to the oral tablet. When adjusted for dose, SPONTAN demonstrated higher dose- normalised bioavailability despite the lower administered dose. Both formulations were well tolerated, with predominantly mild, transient adverse events. Based on the study findings, the investigators concluded that SPONTAN nasal spray demonstrated faster drug absorption and higher dose-normalised bioavailability compared to the oral tablet, with a notably shorter Tmax. This shorter Tmax is expected to translate into a more rapid onset of action with a favourable safety profile, potentially offering greater treatment flexibility for patients with erectile dysfunction who seek immediate treatment and sexual spontaneity. LTR Pharma Scientific Advisory Board member, Professor Eric Chung, said: “The acceptance of this study for an oral podium presentation at WMSM/ESSM 2026 in Porto reflects strong international scientific interest in the SPONTAN nasal spray technology. The pharmacokinetic profile observed highlights the potential advantages of intranasal delivery compared to oral tablets, particularly in terms of clinical safety and speed of drug absorption, which is highly critical to men suffering from erectile dysfunction.” 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) The podium presentation represents international scientific recognition of the SPONTAN Phase 1 study and provides an opportunity to share the findings with the global sexual medicine community. No new clinical data is being disclosed in this announcement. LTR Pharma notes that the study was industry-initiated and sponsored by the Company, with execution and analysis conducted by independent investigators. - ENDS – This announcement has been approved by the Board of Directors. About LTR Pharma LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets. LTR’s lead products, SPONTAN® and ROXUS® , are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW® , a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. LTR Pharma Investor Centre Stay informed with LTR Pharma’s latest announcements and market updates by visiting our Investor Centre or scan the QR code. For further information please contact: Media enquiries Investor enquiries Haley Chartres Peter McLennan haley@hck.digital investors@ltrpharma.com